Rafferty Asset Management
PRME icon

Rafferty Asset Management’s Prime Medicine PRME Stock Holding History

Rafferty Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536K Sell
145,275
-70,307
-33% -$233K ﹤0.01% 883
2026
Q1 		$750K Buy
215,582
+27,871
+15% +$106K ﹤0.01% 830
2025
Q4 		$651K Buy
+187,711
New +$835K ﹤0.01% 869
2023
Q4 		– Sell
-128,876
Closed -$1.23M – 1093
2023
Q3 		$1.23M Buy
+128,876
New +$1.67M 0.01% 738

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Rafferty Asset Management's PRME Position: Q2 2026 in Review

Rafferty Asset Management reduced its Prime Medicine (PRME) stake by 33% in Q2 2026, selling an estimated $233K and leaving 145,275 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Rafferty Asset Management first reported a position in PRME in Q3 2023 and has held it in 4 quarters since. The position peaked at $1.23M in Q3 2023. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Rafferty Asset Management held 145,275 shares of Prime Medicine worth $536K as of Q2 2026.
  • Rafferty Asset Management sold 70,307 Prime Medicine shares in Q2 2026, an estimated $233K.
  • Prime Medicine made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #883 holding.
  • Rafferty Asset Management first reported a position in Prime Medicine in Q3 2023 and has held it in 4 quarters since.
  • Rafferty Asset Management's Prime Medicine position peaked at $1.23M in Q3 2023.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.